减肥
安慰剂
医学
心肌梗塞
不利影响
随机对照试验
相对风险
置信区间
内科学
肥胖
替代医学
病理
作者
Yuchen Guo,Lin Chu,Xiaoling Cai,Han-Fang Wu,Jingya Yan,Zonglin Li,Ruoyang Jiao,Shuzhen Bai,Wenjia Yang,Fang Lv,Geling Liu,Xiaolin Yang,Linong Ji
出处
期刊:iScience
[Elsevier]
日期:2024-09-06
卷期号:27 (10): 110867-110867
标识
DOI:10.1016/j.isci.2024.110867
摘要
The association between anti-obesity medications (AOMs) as well as their weight-loss effects and cardiovascular outcomes need to be comprehensively investigated. We searched PubMed, Embase, the Cochrane Center Register of Controlled Trials for Studies, and Clinicaltrial.gov website from the inception to April 2024 and included 129 randomized controlled trials (RCTs) of AOMs. When compared with placebo, every 5 kg weight reduction mediated by AOMs was associated with the reduced risks of 3-point major adverse cardiovascular events (relative risk [RR] 0.72, 95% confidence interval [CI] 0.60-0.85), myocardial infarction (RR 0.75, 95% CI 0.60-0.95), stroke (RR 0.60, 95% CI 0.42-0.85), and heart failure (RR 0.71, 95% CI 0.54-0.95). As for glucagon-like peptide 1 receptor agonist (GLP-1RA)-users, similar cardiovascular benefits were also observed with 5 kg weight loss. This study indicated that the weight reductions mediated by AOMs were associated with cardiovascular benefits observed in AOM-users.
科研通智能强力驱动
Strongly Powered by AbleSci AI